Diaceutics
Diaceutics operates the DXRX diagnostic network platform, helping top 20 global pharmaceutical companies and emerging biotechs commercialize precision medicines by linking 2,500+ labs across 51 countries, AI-powered multi-modal patient data, and physician engagement workflows.
- Company typePublic
- Founded2005
- HeadquartersBelfast, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Diaceutics does
Diaceutics PLC is a UK-headquartered precision medicine commercialization company, listed on AIM under ticker DXRX, that operates the DXRX diagnostic network platform to connect pharmaceutical companies, laboratories, and treating physicians across the therapy-launch lifecycle. The company works with the top 20 global pharmaceutical companies and a growing cohort of emerging biotechs, and reports involvement on every precision medicine brought to market over its 20+ year history, with therapeutic coverage spanning oncology, rare disease, cardiology, neurology, and autoimmune conditions. The company's stated purpose is closing the gap between diagnostic testing and appropriate therapy selection, addressing documented clinical practice gaps including 64.4% of lung cancer patients not receiving the right treatment per its 2022 JCO Precision Oncology study.
The DXRX platform integrates real-world diagnostic data from a network of 2,500+ laboratories across 51+ countries, encompassing 560 million+ de-identified patient records tokenized through Datavant and result-level data on over 24 million patients, combining lab, genomic, clinical, claims, and social determinants of health inputs. AI and machine learning power a portfolio of products: DXRX Signal (alerts within 24 hours of testing events), physician and lab segmentation modules, a disease testing rate tracker, the Physician Engage activation layer, the Expert Exchange peer-education platform, the 6A Strategic Landscape advisory framework, Targeted Commercialization engagements, and the Diagnostic Audiences product launched with Experian. The underlying stack runs on AWS, Snowflake, and Databricks with Auth0, SendGrid, and Salesforce supporting platform and CRM functions.
Diaceutics generates revenue primarily through multi-year enterprise-wide subscription engagements where customers deploy DXRX across three or more precision medicines in their portfolios, with four such FY2023 deals valued at US$20.1m in aggregate and over 50% of revenue now recurring. FY2025 reported revenue of £38.4m (20% growth), ARR of £20m (19% growth), order book of £38.9m (56% growth), and adjusted EBITDA of £7.6m (80% growth), with a return to £300k profit before tax versus a £1.9m loss in 2024. The company employs approximately 210 people across Belfast (HQ, lease extended to 2036), New York (opened January 2025), Singapore, Seoul, and Ireland.
Diaceutics firmographics
Firmographics- Name
- Diaceutics
- Legal name
- Diaceutics PLC
- Website
- https://diaceutics.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Diaceutics operates the DXRX diagnostic network platform, helping top 20 global pharmaceutical companies and emerging biotechs commercialize precision medicines by linking 2,500+ labs across 51 countries, AI-powered multi-modal patient data, and physician engagement workflows.
- Ownership category
- akta.pro rank
Diaceutics industry classification
Industry- Product category
- Precision Medicine Data & Commercialization Platform
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Diaceutics is headquartered
LocationHeadquarters
- HQ city
- Belfast
- HQ country
- United Kingdom
- HQ region
- Europe
Offices4 records
Markets served
Diaceutics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Enterprise Software Licenses and Platform Subscriptions: Multi-year enterprise-wide engagements with pharmaceutical companies deploying DXRX platform across multiple precision medicines in their portfolio. Characterized by enterprise-wide engagements typically valued at US$20.1 million for four engagements secured in FY 2023.
- Annual Recurring Revenue from Platform Services: ARR of £20m representing 19% growth, driven by increasing platform adoption by large pharma customers. Revenue is approximately 50% recurring in nature.
- Data Services and Analytics: Diagnostic Audiences product integrated into Experian's media-buying workflows for life sciences marketers, enabling campaign activation based on real-time diagnostic signals
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise-wide platform deployments |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Diaceutics product offering
Product offeringCore offering
Diaceutics provides the DXRX diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of 2,500+ laboratories across 50+ countries with AI-powered multi-modal insights (lab, genomic, clinical, claims, SDOH). The platform enables pharmaceutical and biotech companies to identify eligible patients, segment physicians and labs, deliver real-time alerts within 24 hours of testing events, and engage healthcare providers during treatment-decision windows. Adjacent advisory and HCP engagement services (6A Strategic Landscape, Targeted Commercialization, Expert Exchange, Physician Engage) wrap the platform to deliver end-to-end therapy commercialization support.
Product overview
Diaceutics offers a unified platform-plus-modules architecture centered on DXRX, the world's first diagnostic commercialization platform for precision medicine. The core DXRX platform integrates real-world diagnostic data from a global network of laboratories across 50+ countries, providing the foundational data infrastructure. Three product categories extend from this platform: DXRX Data Solutions (DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, DXRX Disease Testing Rate Tracker) for intelligence and analytics; Advisory Solutions (6A Strategic Landscape, Targeted Commercialization) for strategic consulting; and HCP Engagement Solutions (DXRX Physician Engage, Expert Exchange) for physician activation. Additionally, the Diagnostic Audiences product integrates with Experian for marketing workflow automation. Together, these products enable pharma and biotech companies to identify eligible patients, improve diagnostic pathways, and engage healthcare providers at the moments that matter most.
Differentiator
Problem solved
Functional benefit
Brands
- DXRX: The world's first diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of laboratories.
- DXRX Signal
- DXRX Physician Segmentation
- DXRX Lab Segmentation
- DXRX Disease Testing Rate Tracker
- Physician Engage
- Expert Exchange
- PMx
Products and services
- DXRX - The Diagnostic Network The world's first diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of 2,500+ laboratories across 50+ countries. Built for pharmaceutical and biotech companies to support therapy launches and commercialization.
- 6A Strategic Landscape Strategic advisory framework for mapping the precision medicine landscape and identifying commercialization opportunities, offered to pharma and biotech clients.
- Targeted Commercialization Integrated, precision-first commercialization service uniting real-time patient insights, lab and physician behavior intelligence, and digital/expert engagement tools to help pharma teams understand markets, fix testing challenges, and reach eligible patients.
- Expert Exchange Peer-to-peer education service connecting diagnostic experts with treating physicians to drive confident prescribing through trusted clinical voices explaining the test-therapeutic link in a credible, non-promotional format.
- Diagnostic Audiences Clinician-targeting product integrated into Experian's media-buying workflows for life sciences marketers, enabling campaign activation based on real-time diagnostic signals and biomarker results with deterministic, NPI-level precision targeting.
Quantifiable outcome
- DXRX Signal delivers actionable alerts within 24 hours of testing behaviour, enabling engagement during treatment decisions
- +3 more outcomes
Companies that use Diaceutics
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Diaceutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
AI capability7 records
Feature6 records
Diaceutics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and support.
- ExperiancoreDiaceutics and Experian partnered to integrate real-time AI-driven diagnostic data into pharmaceutical marketing workflows. The collaboration embeds Diaceutics' Diagnostic Audiences into Experian's marketing platform, enabling deterministic, NPI-level precision targeting based on observed clinical events rather than retrospective prescription or claims data. The data refreshes daily, creating a near real-time feedback loop for campaign optimization.
- KPMGcoreStrategic alliance to bring together Diaceutics' leading technology solutions and KPMG's market-leading advisory business for jointly marketing commercialisation solutions to life science customers launching precision medicines. Combines Diaceutics' data expertise with KPMG's global customer base and experience across precision medicine commercialisation and deal making.
- Personalized Medicine CoalitioncoreCollaboration on Clinical Practice Gaps study published in JCO Precision Oncology, working with broad stakeholder group across the Personalized Medicine Coalition to identify barriers preventing patients from receiving specialized treatments.
- DatavantcoreData partnership enabling tokenization of over 560 million de-identified patients through Datavant's infrastructure for privacy-preserving data collaboration.
- AWScoreCloud service provider where the DXRX SaaS platform is hosted, based in Ireland.
- SnowflakecoreSaaS-based data warehouse for the DXRX SaaS platform, enabling large-scale data processing and analytics.
- SalesforcesupportCustomer CRM used for managing customer relationships and marketing campaigns.
Scale indicators12 records
Recent moves7 records
Expansion highlights6 records
Diaceutics competitors and assessment
Company assessmentBroad incumbents
- IQVIA: The largest real-world data and pharma commercial analytics provider globally. Overlaps with Diaceutics on real-world diagnostic data and pharma commercialization analytics, but offers a much broader portfolio spanning clinical, commercial, and technology services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Diaceutics social profiles
Digital presenceDiaceutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diaceutics leadership team
Management profileNumber of profiles
Profiles11 records
Diaceutics subsidiaries and ownership
Company hierarchySubsidiaries4 records
Diaceutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diaceutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diaceutics
What does Diaceutics do?
Diaceutics provides the DXRX diagnostic commercialization platform for precision medicine, integrating real-world diagnostic data from a global network of 2,500+ laboratories across 50+ countries with AI-powered multi-modal insights (lab, genomic, clinical, claims, SDOH). The platform enables pharmaceutical and biotech companies to identify eligible patients, segment physicians and labs, deliver real-time alerts within 24 hours of testing events, and engage healthcare providers during treatment-decision windows. Adjacent advisory and HCP engagement services (6A Strategic Landscape, Targeted Commercialization, Expert Exchange, Physician Engage) wrap the platform to deliver end-to-end therapy commercialization support.
Is Diaceutics a public or private company?
Diaceutics is a public company. It is classified as public and is currently operating.
When was Diaceutics founded?
Diaceutics was founded in 2005. It employs 101 to 250 people.
Where is Diaceutics based?
Diaceutics is headquartered in Belfast, United Kingdom, in the Europe region.
How does Diaceutics make money?
Three revenue lines are on record. Enterprise Software Licenses and Platform Subscriptions are the primary driver. The others are annual Recurring Revenue from Platform Services and data Services and Analytics.
Who are Diaceutics's main competitors?
IQVIA is listed as a broad incumbent.
Does Diaceutics have an API?
No public API is recorded for Diaceutics.
What industry is Diaceutics in?
Diaceutics's product category is Precision Medicine Data & Commercialization Platform. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5132 and its SIC code is 7372.